[DPHARMA] QoQ Cumulative Quarter Result on 30-Sep-2017 [#3]
Announcement Date
17-Nov-2017
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2017
Quarter
30-Sep-2017 [#3]
Profit Trend
QoQ- 59.35%
YoY- 62.3%
Quarter Report
View:
Show?
| Cumulative Result | |||||||||
| 30/06/18 | 31/03/18 | 31/12/17 | 30/09/17 | 30/06/17 | 31/03/17 | 31/12/16 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 257,250 | 133,259 | 467,987 | 355,734 | 240,355 | 120,994 | 312,940 | -12.27% | |
| PBT | 26,170 | 13,255 | 51,796 | 38,971 | 24,764 | 11,176 | 31,479 | -11.61% | |
| Tax | -5,184 | -2,608 | -9,696 | -8,639 | -5,559 | -2,558 | -4,653 | 7.49% | |
| NP | 20,986 | 10,647 | 42,100 | 30,332 | 19,205 | 8,618 | 26,826 | -15.13% | |
| - | |||||||||
| NP to SH | 20,986 | 10,782 | 42,492 | 30,622 | 19,217 | 8,618 | 27,115 | -15.74% | |
| - | |||||||||
| Tax Rate | 19.81% | 19.68% | 18.72% | 22.17% | 22.45% | 22.89% | 14.78% | - | |
| Total Cost | 236,264 | 122,612 | 425,887 | 325,402 | 221,150 | 112,376 | 286,114 | -12.01% | |
| - | |||||||||
| Net Worth | 209,983 | 206,429 | 479,809 | 474,230 | 463,071 | 463,071 | 454,703 | -40.33% | |
| Dividend | |||||||||
| 30/06/18 | 31/03/18 | 31/12/17 | 30/09/17 | 30/06/17 | 31/03/17 | 31/12/16 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|
| Div | 4,199 | - | 23,711 | - | 6,973 | - | 18,132 | -62.39% | |
| Div Payout % | 20.01% | - | 55.80% | - | 36.29% | - | 66.87% | - | |
| Equity | |||||||||
| 30/06/18 | 31/03/18 | 31/12/17 | 30/09/17 | 30/06/17 | 31/03/17 | 31/12/16 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|
| Net Worth | 209,983 | 206,429 | 479,809 | 474,230 | 463,071 | 463,071 | 454,703 | -40.33% | |
| NOSH | 650,902 | 278,959 | 278,959 | 278,959 | 278,959 | 278,959 | 278,959 | 76.19% | |
| Ratio Analysis | |||||||||
| 30/06/18 | 31/03/18 | 31/12/17 | 30/09/17 | 30/06/17 | 31/03/17 | 31/12/16 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|
| NP Margin | 8.16% | 7.99% | 9.00% | 8.53% | 7.99% | 7.12% | 8.57% | - | |
| ROE | 9.99% | 5.22% | 8.86% | 6.46% | 4.15% | 1.86% | 5.96% | - | |
| Per Share | |||||||||
| 30/06/18 | 31/03/18 | 31/12/17 | 30/09/17 | 30/06/17 | 31/03/17 | 31/12/16 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|
| RPS | 91.88 | 47.77 | 167.76 | 127.52 | 86.16 | 43.37 | 112.18 | -12.49% | |
| EPS | 3.22 | 3.82 | 15.09 | 10.87 | 6.88 | 3.43 | 9.62 | -51.88% | |
| DPS | 1.50 | 0.00 | 8.50 | 0.00 | 2.50 | 0.00 | 6.50 | -62.47% | |
| NAPS | 0.75 | 0.74 | 1.72 | 1.70 | 1.66 | 1.66 | 1.63 | -40.48% | |
| Adjusted Per Share Value based on latest NOSH - 278,959 | |||||||||
| 30/06/18 | 31/03/18 | 31/12/17 | 30/09/17 | 30/06/17 | 31/03/17 | 31/12/16 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|
| RPS | 26.74 | 13.85 | 48.65 | 36.98 | 24.99 | 12.58 | 32.53 | -12.28% | |
| EPS | 2.18 | 1.12 | 4.42 | 3.18 | 2.00 | 0.90 | 2.82 | -15.80% | |
| DPS | 0.44 | 0.00 | 2.46 | 0.00 | 0.72 | 0.00 | 1.88 | -62.12% | |
| NAPS | 0.2183 | 0.2146 | 0.4988 | 0.493 | 0.4814 | 0.4814 | 0.4727 | -40.33% | |
| Price Multiplier on Financial Quarter End Date | |||||||||
| 30/06/18 | 31/03/18 | 31/12/17 | 30/09/17 | 30/06/17 | 31/03/17 | 31/12/16 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|
| Date | 29/06/18 | 30/03/18 | 29/12/17 | 29/09/17 | 30/06/17 | 31/03/17 | 30/12/16 | - | |
| Price | 1.30 | 2.80 | 2.53 | 2.20 | 2.25 | 2.31 | 1.98 | - | |
| P/RPS | 1.41 | 5.86 | 1.51 | 1.73 | 2.61 | 5.33 | 1.76 | -13.77% | |
| P/EPS | 17.34 | 72.44 | 16.61 | 20.04 | 32.66 | 74.77 | 20.37 | -10.20% | |
| EY | 5.77 | 1.38 | 6.02 | 4.99 | 3.06 | 1.34 | 4.91 | 11.39% | |
| DY | 1.15 | 0.00 | 3.36 | 0.00 | 1.11 | 0.00 | 3.28 | -50.37% | |
| P/NAPS | 1.73 | 3.78 | 1.47 | 1.29 | 1.36 | 1.39 | 1.21 | 26.99% | |
| Price Multiplier on Announcement Date | |||||||||
| 30/06/18 | 31/03/18 | 31/12/17 | 30/09/17 | 30/06/17 | 31/03/17 | 31/12/16 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|
| Date | 26/11/18 | 28/05/18 | 28/02/18 | 17/11/17 | 25/08/17 | 22/05/17 | 24/02/17 | - | |
| Price | 1.08 | 3.35 | 2.97 | 2.20 | 2.03 | 2.32 | 2.23 | - | |
| P/RPS | 1.18 | 7.01 | 1.77 | 1.73 | 2.36 | 5.35 | 1.99 | -29.48% | |
| P/EPS | 14.41 | 86.67 | 19.50 | 20.04 | 29.47 | 75.10 | 22.94 | -26.71% | |
| EY | 6.94 | 1.15 | 5.13 | 4.99 | 3.39 | 1.33 | 4.36 | 36.44% | |
| DY | 1.39 | 0.00 | 2.86 | 0.00 | 1.23 | 0.00 | 2.91 | -38.97% | |
| P/NAPS | 1.44 | 4.53 | 1.73 | 1.29 | 1.22 | 1.40 | 1.37 | 3.38% | |
PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
All figures in '000 unless specified.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
Mercury Securities Research
2
Stock Market Enthusiast
3
THE INVESTMENT APPROACH OF CALVIN TAN
4
5
Phillip Capital Research Reports
6
7
Good Articles to Share
8
save malaysia!
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
